Berufsausübungsgemeinschaft Dr. Jörg Schulze
- Address
- lock Available on a paid plan
Berufsausübungsgemeinschaft Dr. Jörg Schulze - Gastrointestinal Research Center
This medical research center specializes in gastrointestinal disorders with a particular focus on functional bowel conditions. The facility conducts advanced clinical trials investigating novel therapeutic approaches for patients suffering from chronic digestive system disorders, with expertise in evaluating both pharmacological and probiotic interventions.
- Irritable Bowel Syndrome with diarrhea predominance (IBS-D)
- Probiotic and microbiome-based therapeutic interventions
- Functional gastrointestinal disorder management
The center has demonstrated expertise in conducting randomized, double-blind, placebo-controlled trials, focusing on evaluating the efficacy, safety, and tolerability of innovative treatments. Research efforts include investigating bacterial strain therapies such as E. coli DSM 17252 for managing chronic gastrointestinal symptoms, contributing to the advancement of microbiome-based therapeutics in the treatment of functional bowel disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Janssen Cilag International2active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Berufsausübungsgemeinschaft Dr. Jörg Schulze
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease | Janssen Cilag International | Phase IV | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| ICOTROKINRA | 2 | Unknown | 2025-12-03 | 2025-12-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.